Hookipa Pharma (HOOK) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Hookipa Pharma in October 2026.
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Hookipa Pharma (HOOK) Stock Forecast
Analyst price target, next 12 months
$32.33
+2114.6% vs today's $1.46
Price range over the last 12 months
Close to its 12-month low
Analysts covering Hookipa Pharma have a consensus 12-month target of $32.33, above the current price of $1.46.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 12 Jun 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying HOOKIPA Pharma's stock with a target price of $34.25, indicating significant growth potential.
Financial Health
HOOKIPA Pharma is generating modest revenue and cash flow, but its financial position is stable.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
